<p>Myomo Inc ((MYO)) 举行了第三季度财报电话会议。请继续阅读会议的主要亮点。</p>
<h3>认识你的 ETF AI 分析师</h3>
<ul>
<li>了解 TipRanks 的 <em>ETF</em> AI 分析师如何帮助你做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> AI 分析师</strong> 对你关注的 ETF 的见解。</li>
</ul>
<p>Myomo Inc. 最近的财报电话会议描绘了一个复杂的局面，既有增长也有挑战。公司报告了显著的收入增长和战略扩展，特别是在国际市场和 O&amp;P 渠道。然而，关于毛利率下降、运营亏损增加和高现金消耗的担忧被提出。尽管对财务指引的重申以及优化成本和广告的措施是积极的，但 Medicare Advantage 收入的问题和亏损的增加仍然是重大障碍。</p>
<h2>收入增长与国际成功</h2>
<p>Myomo 报告称，2025 年第三季度收入为 1010 万美元，比去年增长 10%。这一增长得益于国际市场的创纪录收入，其中德国表现突出。来自德国的国际收入单独达到了创纪录的 180 万美元，比去年增长 63%。</p>
<h2>授权和订单增加</h2>
<p>今年首次，Myomo 体验到了季度授权和订单的连续增长。这一增长得益于 Medicare Advantage 付款方授权的增加，表明该领域的积极趋势。</p>
<h2>扩大 O&amp;P 渠道</h2>
<p>公司的 O&amp;P 渠道年同比收入增长了 154%，达到了 90 万美元。这一扩展是 Myomo 战略努力的一部分，旨在增强市场存在感并推动增长。</p>
<h2>成本降低与运营杠杆</h2>
<p>Myomo 已采取措施降低运营成本并改善毛利率。公司还在优化广告支出并扩展 MyoConnect 项目，旨在增强运营杠杆并实现成本效率。</p>
<h2>财务指引重申</h2>
<p>Myomo 重申其 2025 年全年的收入指引为 4000 万至 4200 万美元，比去年增长超过 23%。这一乐观展望得益于强劲的第三季度表现和旨在可持续增长的战略举措。</p>
<h2>Medicare Advantage 收入下降</h2>
<p>尽管授权呈积极趋势，Medicare Advantage 收入较去年下降了 18%。这一下降归因于高预授权拒绝率，导致耗时的上诉过程。</p>
<h2>毛利率下降</h2>
<p>2025 年第三季度的毛利率为 63.8%，低于去年同期的 75.4%。这一下降受到更高的工资和租赁费用、材料成本以及不利的间接费用吸收的影响。</p>
<h2>运营亏损增加</h2>
<p>2025 年第三季度的运营亏损增加至 350 万美元，而去年为 100 万美元。净亏损也从 100 万美元上升至 370 万美元，突显了公司面临的财务挑战。</p>
<h2>高现金消耗</h2>
<p>2025 年第三季度的现金消耗为 290 万美元，主要由与制造空间扩展和产品开发相关的运营活动和资本支出驱动。这仍然是公司面临的一个关键关注领域。</p>
<h2>前瞻性指引</h2>
<p>在财报电话会议上，首席执行官 Paul Gudonis 提供了指引，Myomo 预计 2025 年全年的收入将在 4000 万至 4200 万美元之间，反映出比去年增长超过 23%。公司专注于扩展其 MyoConnect 项目和 O&amp;P 渠道，以降低客户获取成本并改善运营杠杆。战略举措包括扩大保险覆盖范围和增强患者识别流程，承诺朝着可持续盈利和正现金流的方向发展。</p>
<p>总之，Myomo 的财报电话会议突显了既有希望的增长又有重大挑战。公司的战略扩展和国际市场的收入增长令人鼓舞，但毛利率下降和运营亏损增加等问题仍然构成挑战。对财务指引的重申以及旨在优化成本和市场扩展的战略举措为未来提供了希望的前景。</p>

<p>Myomo Inc. 举行了第三季度财报电话会议，报告收入增长 10%，达到 1010 万美元，主要得益于国际市场，尤其是德国。然而，面临的挑战包括毛利率下降（从 75.4% 降至 63.8%）、经营亏损增加（350 万美元）以及高额现金消耗（290 万美元）。该公司重申了 2025 年收入指导目标为 4000 万至 4200 万美元，尽管医疗保险优势收入下降了 18%，仍专注于成本优化和市场扩展。Myomo 的战略举措旨在在这些财务挑战中实现可持续增长</p>

<p>Myomo Inc ((MYO)) has held its Q3 earnings call. Read on for the main highlights of the call.</p>
<div class="lb-trans"><p>Myomo Inc ((MYO)) 举行了第三季度财报电话会议。请继续阅读会议的主要亮点。</p>
</div><h3>Meet Your ETF AI Analyst</h3>
<div class="lb-trans"><h3>认识你的 ETF AI 分析师</h3>
</div><ul>
<li>Discover how TipRanks' <em>ETF</em> AI Analyst can help you make smarter investment decisions</li>
<li>Explore ETFs TipRanks' users love and see what insights the <strong><em>ETF</em> AI Analyst</strong> reveals about the ones you follow.</li>
</ul>
<div class="lb-trans"><ul>
<li>了解 TipRanks 的 <em>ETF</em> AI 分析师如何帮助你做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> AI 分析师</strong> 对你关注的 ETF 的见解。</li>
</ul>
</div><p>The recent earnings call for Myomo Inc. painted a mixed picture, highlighting both growth and challenges. The company reported notable revenue growth and strategic expansions, particularly in international markets and the O&amp;P channel. However, concerns were raised over decreased gross margins, increased operating losses, and high cash burn. While the reaffirmation of financial guidance and steps to optimize costs and advertising were positive, issues with Medicare Advantage revenue and increased losses remain significant hurdles.</p>
<div class="lb-trans"><p>Myomo Inc. 最近的财报电话会议描绘了一个复杂的局面，既有增长也有挑战。公司报告了显著的收入增长和战略扩展，特别是在国际市场和 O&amp;P 渠道。然而，关于毛利率下降、运营亏损增加和高现金消耗的担忧被提出。尽管对财务指引的重申以及优化成本和广告的措施是积极的，但 Medicare Advantage 收入的问题和亏损的增加仍然是重大障碍。</p>
</div><h2>Revenue Growth and International Success</h2>
<div class="lb-trans"><h2>收入增长与国际成功</h2>
</div><p>Myomo reported a revenue of $10.1 million for Q3 2025, marking a 10% increase compared to the prior year. This growth was driven by record revenues in international markets, with Germany being a standout performer. The international revenue from Germany alone reached a record $1.8 million, up 63% from the previous year.</p>
<div class="lb-trans"><p>Myomo 报告称，2025 年第三季度收入为 1010 万美元，比去年增长 10%。这一增长得益于国际市场的创纪录收入，其中德国表现突出。来自德国的国际收入单独达到了创纪录的 180 万美元，比去年增长 63%。</p>
</div><h2>Increased Authorizations and Orders</h2>
<div class="lb-trans"><h2>授权和订单增加</h2>
</div><p>For the first time this year, Myomo experienced a sequential increase in quarterly authorizations and orders. This growth was supported by an increase in Medicare Advantage payer authorizations, signaling a positive trend in this area.</p>
<div class="lb-trans"><p>今年首次，Myomo 体验到了季度授权和订单的连续增长。这一增长得益于 Medicare Advantage 付款方授权的增加，表明该领域的积极趋势。</p>
</div><h2>Expanding O&amp;P Channel</h2>
<div class="lb-trans"><h2>扩大 O&amp;P 渠道</h2>
</div><p>The company’s O&amp;P channel saw a significant revenue increase of 154% year over year, reaching $900,000. This expansion is part of Myomo’s strategic efforts to enhance its market presence and drive growth.</p>
<div class="lb-trans"><p>公司的 O&amp;P 渠道年同比收入增长了 154%，达到了 90 万美元。这一扩展是 Myomo 战略努力的一部分，旨在增强市场存在感并推动增长。</p>
</div><h2>Cost Reduction and Operating Leverage</h2>
<div class="lb-trans"><h2>成本降低与运营杠杆</h2>
</div><p>Myomo has taken steps to reduce operating costs and improve gross margins. The company is also optimizing advertising spend and expanding the MyoConnect program, aiming to enhance operating leverage and achieve cost efficiencies.</p>
<div class="lb-trans"><p>Myomo 已采取措施降低运营成本并改善毛利率。公司还在优化广告支出并扩展 MyoConnect 项目，旨在增强运营杠杆并实现成本效率。</p>
</div><h2>Financial Guidance Reaffirmed</h2>
<div class="lb-trans"><h2>财务指引重申</h2>
</div><p>Myomo reiterated its full-year 2025 revenue guidance of $40 million to $42 million, representing an increase of more than 23% over the previous year. This optimistic outlook is supported by strong third-quarter performance and strategic initiatives aimed at sustainable growth.</p>
<div class="lb-trans"><p>Myomo 重申其 2025 年全年的收入指引为 4000 万至 4200 万美元，比去年增长超过 23%。这一乐观展望得益于强劲的第三季度表现和旨在可持续增长的战略举措。</p>
</div><h2>Decline in Medicare Advantage Revenue</h2>
<div class="lb-trans"><h2>Medicare Advantage 收入下降</h2>
</div><p>Despite positive trends in authorizations, Medicare Advantage revenue was down 18% compared to the prior year. This decline was attributed to high pre-authorization denial rates, leading to a time-consuming appeals process.</p>
<div class="lb-trans"><p>尽管授权呈积极趋势，Medicare Advantage 收入较去年下降了 18%。这一下降归因于高预授权拒绝率，导致耗时的上诉过程。</p>
</div><h2>Decreased Gross Margin</h2>
<div class="lb-trans"><h2>毛利率下降</h2>
</div><p>The gross margin for Q3 2025 was 63.8%, down from 75.4% in the prior year. This decrease was impacted by higher payroll and lease expenses, material costs, and unfavorable overhead absorption.</p>
<div class="lb-trans"><p>2025 年第三季度的毛利率为 63.8%，低于去年同期的 75.4%。这一下降受到更高的工资和租赁费用、材料成本以及不利的间接费用吸收的影响。</p>
</div><h2>Increased Operating Loss</h2>
<div class="lb-trans"><h2>运营亏损增加</h2>
</div><p>The operating loss for Q3 2025 increased to $3.5 million, compared to $1 million in the prior year. The net loss also rose to $3.7 million from $1 million, highlighting the financial challenges the company faces.</p>
<div class="lb-trans"><p>2025 年第三季度的运营亏损增加至 350 万美元，而去年为 100 万美元。净亏损也从 100 万美元上升至 370 万美元，突显了公司面临的财务挑战。</p>
</div><h2>High Cash Burn</h2>
<div class="lb-trans"><h2>高现金消耗</h2>
</div><p>Cash burn was $2.9 million in Q3 2025, driven by operating activities and capital expenditures related to manufacturing space expansion and product development. This remains a critical area of concern for the company.</p>
<div class="lb-trans"><p>2025 年第三季度的现金消耗为 290 万美元，主要由与制造空间扩展和产品开发相关的运营活动和资本支出驱动。这仍然是公司面临的一个关键关注领域。</p>
</div><h2>Forward-Looking Guidance</h2>
<div class="lb-trans"><h2>前瞻性指引</h2>
</div><p>During the earnings call, CEO Paul Gudonis provided guidance that Myomo anticipates achieving full-year 2025 revenue within the range of $40 million to $42 million, reflecting an over 23% increase compared to the previous year. The company is focusing on expanding its MyoConnect program and O&amp;P channel to lower customer acquisition costs and improve operating leverage. Strategic initiatives include expanding insurance coverage and enhancing patient identification processes, with a commitment to scaling towards sustainable profitability and positive cash flow.</p>
<div class="lb-trans"><p>在财报电话会议上，首席执行官 Paul Gudonis 提供了指引，Myomo 预计 2025 年全年的收入将在 4000 万至 4200 万美元之间，反映出比去年增长超过 23%。公司专注于扩展其 MyoConnect 项目和 O&amp;P 渠道，以降低客户获取成本并改善运营杠杆。战略举措包括扩大保险覆盖范围和增强患者识别流程，承诺朝着可持续盈利和正现金流的方向发展。</p>
</div><p>In summary, Myomo’s earnings call highlighted both promising growth and significant challenges. The company’s strategic expansions and revenue growth in international markets are encouraging, yet issues such as decreased gross margins and increased operating losses pose challenges. The reaffirmation of financial guidance and strategic initiatives aimed at cost optimization and market expansion provide a hopeful outlook for the future.</p>
<div class="lb-trans"><p>总之，Myomo 的财报电话会议突显了既有希望的增长又有重大挑战。公司的战略扩展和国际市场的收入增长令人鼓舞，但毛利率下降和运营亏损增加等问题仍然构成挑战。对财务指引的重申以及旨在优化成本和市场扩展的战略举措为未来提供了希望的前景。</p>
</div>

Myomo Inc. 财报电话会议：在挑战中实现增长